Christine D. Dijkstra

Peter MacCallum Cancer Centre — Australia

Medicine · Health Sciences

61h-index12.1kcitations183works1.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Sclerosis Research Studies(31), Immune Cell Function and Interaction(30), Neuroinflammation and Neurodegeneration Mechanisms(28), Immunotherapy and Immune Responses(25), Immune Response and Inflammation(21)

Publications182 total

762MO Clinical whole genome and transcriptome sequencing for cancer of unknown primary: An Australian prospective observational study
Annals of Oncology·2025
Understanding the clinical and molecular phenotype of cancer of unknown primary (CUP) with a lung cancer profile.
Journal of Clinical Oncology·2025
Protocol on utilizing murine gastric cancer organoids for modeling subcutaneous, orthotopic primary, and liver metastatic disease in mice
STAR Protocols·2025· 1 citedOpen Access
Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines
Cell Reports·2024· 13 citedOpen Access
Clinical impact of molecular profiling in the national prospective cohort Solving Unknown Primary Cancer (SUPER) study.
Journal of Clinical Oncology·2024
Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within Interleukin-6 family cytokines
2024· 1 citedOpen Access
Abstract 2698: TCF-1 is a critical regulator of intraepithelial lymphocytes in colorectal carcinoma
Cancer Research·2024
Overview of Standard Therapy of Non-Muscle-Invasive Bladder Cancer
2024
1038 T cell factor 1 (TCF-1) is a molecular checkpoint in colorectal carcinoma γδ T cell immunity
Regular and Young Investigator Award Abstracts·2023Open Access
TCF-1 limits intraepithelial lymphocyte antitumor immunity in colorectal carcinoma
Science Immunology·2023· 23 citedOpen Access
Supplementary Figure S2 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
Supplementary Figure S3 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
Supplementary Figure S3 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
Supplementary Figure S1 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
Supplementary Figure S5 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
Supplementary Figure S6 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
Supplementary Table 1 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
Data from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
Supplementary Figure S4 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
Supplementary Figure S5 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Helga E. de Vries(20), Timo K. van den Berg(14), Susanne M. A. van der Pol(12), Paul van der Valk(9), Priscilla Heijnen(7), Gijs Kooij(7), Arie Reijerkerk(7), Sandra Amor(6), Jack van Horssen(6), Ed A. Döpp(6), Daphne Y.S. Vogel(5), Charlotte E. Teunissen(5), Babs O. Fabriek(5), Jerome J. A. Hendriks(5), Marjolein Breur(4), Nico van Rooijen(4), Machteld M. J. Polfliet(4), Gerty Schreibelt(3), Ruben van Doorn(3), Eric Ronken(3)